Intravenous Infusions (XGHA:IIL) LT-Debt-to-Total-Asset: 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Intravenous Infusions LT-Debt-to-Total-Asset?

Intravenous Infusions XGHA:IIL +8.86% LT-Debt-to-Total-Asset is 0.00 as of . 20.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Intravenous Infusions's long-term debt to total assests ratio for the quarter that ended in . 20 was 0.00.

Intravenous Infusions's long-term debt to total assets ratio stayed the same from . 20 (0.00) to . 20 (0.00).

Intravenous Infusions  (XGHA:IIL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Intravenous Infusions LT-Debt-to-Total-Asset Related Terms

Intravenous Infusions LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Intravenous Infusions's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intravenous Infusions LT-Debt-to-Total-Asset Chart

Intravenous Infusions Annual Data
Trend
LT-Debt-to-Total-Asset

Intravenous Infusions Semi-Annual Data
LT-Debt-to-Total-Asset

Intravenous Infusions LT-Debt-to-Total-Asset Calculation

Intravenous Infusions's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in . 20 is calculated as

LT Debt to Total Assets (A: . 20 )=Long-Term Debt & Capital Lease Obligation (A: . 20 )/Total Assets (A: . 20 )
=/
=

Intravenous Infusions's Long-Term Debt to Total Asset Ratio for the quarter that ended in . 20 is calculated as

LT Debt to Total Assets (Q: . 20 )=Long-Term Debt & Capital Lease Obligation (Q: . 20 )/Total Assets (Q: . 20 )
=/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Intravenous Infusions (XGHA:IIL) has a LT-Debt-to-Total-Asset of 0.00 as of . 20. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Intravenous Infusions and its competitors.
Is Intravenous Infusions' LT-Debt-to-Total-Asset too high?
Intravenous Infusions' current LT-Debt-to-Total-Asset is 0.00.
How does Intravenous Infusions' LT-Debt-to-Total-Asset compare to PTLF and PCYN?
Intravenous Infusions' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Intravenous Infusions and its competitors. Intravenous Infusions's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current LT-Debt-to-Total-Asset is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intravenous Infusions Business Description

Address Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.